AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23911604 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic re‐isolates
Number of subjects: 4
Study 23911604 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic isolates
Number of subjects: 4
Study 23911604 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial gene expression profiles
Number of subjects: 4
Study 22151148 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health nurse/peer counselor intervention
Number of subjects: 328
Study 22151148 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 328
Study 20013882 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich 2:1 dry mix of red wine and red grape juice extracts (MIX)
Number of subjects: 58
Study 20013882 — intervention group
Group type: EXPERIMENTAL
Intervention: Only a grape juice extract (GJX)
Number of subjects: 58
Study 20013882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 19094529 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty with a tourniquet
Number of subjects: 60
Study 19094529 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty without a tourniquet
Number of subjects: 60
Study 16241946 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (2.5 mg b.i.d.)
Number of subjects: 621
Study 16241946 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (5 mg b.i.d.)
Number of subjects: 621
Study 16241946 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (10 mg b.i.d.)
Number of subjects: 621
Study 16241946 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (20 mg b.i.d.)
Number of subjects: 621
Study 16241946 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (30 mg b.i.d.)
Number of subjects: 621
Study 16241946 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (30 mg b.i.d.)
Number of subjects: 621
Study 16241946 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (all doses)
Number of subjects: 621
Study 16241946 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (2.5-10 mg b.i.d.)
Number of subjects: 621
Study 12133066 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasal lavage with 50 mL of normal saline
Number of subjects: 72
Study 12133066 — intervention group
Group type: COMPARATOR
Intervention: No vasal lavage (control group)
Number of subjects: 72
Study 10102093 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional bracing
Number of subjects: 0
Study 10102093 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoprene sleeve
Number of subjects: 0
Study 10102093 — intervention group
Group type: COMPARATOR
Intervention: ACL-deficient knee
Number of subjects: 0
Study 7554636 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic division
Number of subjects: 40
Study 7554636 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopy and manipulation
Number of subjects: 40
Study 2160414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) injection of CY 216, 100 anti-factor Xa IC U/kg
Number of subjects: 12
Study 2160414 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) injection of CY 216, 100 anti-factor Xa IC U/kg
Number of subjects: 12
Study 335197 — intervention group
Group type: EXPERIMENTAL
Intervention: co-trimoxazole
Number of subjects: 105
Study 335197 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxycillin
Number of subjects: 105
Study 31099219 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture artificial menstrual cycle method
Number of subjects: 60
Study 31099219 — intervention group
Group type: COMPARATOR
Intervention: Medication artificial menstrual cycle method (Femoston)
Number of subjects: 60
Study 28829526 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-ADER-IMT 60 mg
Number of subjects: 115
Study 28829526 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-ADER-IMT 30 mg
Number of subjects: 115
Study 28829526 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-ADER-IMT 2 ȕ 15 mg
Number of subjects: 115
Study 28829526 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-ADER-IMT
Number of subjects: 115
Study 26244354 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid foam 15%
Number of subjects: 0
Study 26244354 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 23551324 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA 15 J/cm(2) /session
Number of subjects: 45
Study 23551324 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA
Number of subjects: 45
Study 23551324 — intervention group
Group type: COMPARATOR
Intervention: UVA 10 J/cm(2) /session
Number of subjects: 45
Study 21756378 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone Valerate 0.2% plus Hyaluronidase
Number of subjects: 195
Study 21756378 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone Valerate 0.2%
Number of subjects: 195
Study 21756378 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone Valerate 0.1%
Number of subjects: 195
Study 21756378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 19430059 — intervention group
Group type: EXPERIMENTAL
Intervention: EVOH fiber underwear
Number of subjects: 21
Study 19430059 — intervention group
Group type: COMPARATOR
Intervention: Control group (cotton underwear)
Number of subjects: 21
Study 16919986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel Node Biopsy (SNB) followed by Elective Neck Dissection (END)
Number of subjects: 55
Study 16919986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel Node Biopsy (SNB) without Elective Neck Dissection (END)
Number of subjects: 55
Study 16919986 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Sentinel Node Biopsy (SNB) procedure
Number of subjects: 55
Study 15117384 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Choice leaflets
Number of subjects: 0
Study 15117384 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid implementation packages
Number of subjects: 0
Study 10917323 — intervention group
Group type: EXPERIMENTAL
Intervention: LET (lidocaine 2%, epinephrine 1:1,000, tetracaine 2%)
Number of subjects: 43
Study 10917323 — intervention group
Group type: COMPARATOR
Intervention: Placebo (epinephrine 1:1,000)
Number of subjects: 43
Study 9048348 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly subcutaneous (SC) rHuEPO at one third the weekly IV dose for 10 months
Number of subjects: 44
Study 9048348 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous (IV) rHuEPO therapy
Number of subjects: 44
Study 8315262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, 500 mg daily (about 8.7 mg/kg body weight)
Number of subjects: 88
Study 8315262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 3443140 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate 100 mg orally
Number of subjects: 18
Study 3443140 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate 200 mg orally
Number of subjects: 18
Study 3443140 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate 20 mg as a constant‐rate intravenous infusion over 20 min
Number of subjects: 18
Study 3443140 — intervention group
Group type: COMPARATOR
Intervention: Smokers (S) vs Nonsmokers (NS)
Number of subjects: 18
Study 3443140 — intervention group
Group type: COMPARATOR
Intervention: Males (M) vs Females (FM)
Number of subjects: 18
Study 28643056 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB)
Number of subjects: 34
Study 27158851 — intervention group
Group type: EXPERIMENTAL
Intervention: EVOLUTION: Young Women Taking Charge and Growing Stronger (behavioral intervention)
Number of subjects: 0
Study 27158851 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 23980121 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP training for first-generation nurses
Number of subjects: 28
Study 23980121 — intervention group
Group type: COMPARATOR
Intervention: CPAP training for second-generation nurses
Number of subjects: 28
Study 23034417 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia cantilever FDPs (test group)
Number of subjects: 21
Study 23034417 — intervention group
Group type: COMPARATOR
Intervention: Metal-ceramic cantilever FDPs (control group)
Number of subjects: 21
Study 23034417 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 20724647 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g C10
Number of subjects: 0
Study 20724647 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 g C10
Number of subjects: 0
Study 20724647 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 g C10 (substituted for fats)
Number of subjects: 0
Study 20724647 — intervention group
Group type: EXPERIMENTAL
Intervention: C10 (in L6 muscle cells)
Number of subjects: 0
Study 20724647 — intervention group
Group type: EXPERIMENTAL
Intervention: C10
Number of subjects: 0
Study 20724647 — intervention group
Group type: COMPARATOR
Intervention: 0 g (control)
Number of subjects: 0
Study 18272089 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg dexamethasone intravenously
Number of subjects: 115
Study 18272089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 15709187 — intervention group
Group type: EXPERIMENTAL
Intervention: mTOR kinase inhibitor CCI‐779
Number of subjects: 45
Study 12566371 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (30 mg/d, median, range: 10 to 40 mg/d)
Number of subjects: 28
Study 12566371 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg/d)
Number of subjects: 28
Study 12566371 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (maximum doses)
Number of subjects: 28
Study 12566371 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 28
Study 10687257 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg daily)
Number of subjects: 16
Study 10687257 — intervention group
Group type: COMPARATOR
Intervention: Trimetazidine (20 mg 3 times daily)
Number of subjects: 16
Study 8684197 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-managed care
Number of subjects: 1299
Study 8684197 — intervention group
Group type: COMPARATOR
Intervention: Shared care
Number of subjects: 1299
Study 1896268 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mL/kg of 1% lidocaine prior to the lumbar puncture
Number of subjects: 81
Study 1896268 — intervention group
Group type: COMPARATOR
Intervention: Nonanesthetized lumbar puncture without placebo
Number of subjects: 81
Study 6414822 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg/day for 2.5 days
Number of subjects: 9
Study 6414822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6414822 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine 0.2 mg/kg intravenous injection after indomethacin
Number of subjects: 9
Study 6414822 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine 0.2 mg/kg intravenous injection after placebo
Number of subjects: 9
Study 6414822 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin vs. Placebo
Number of subjects: 9
Study 31326947 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated prognostic tool based on validated risk calculators
Number of subjects: 1049
Study 31326947 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual behaviour risk factors
Number of subjects: 1049
Study 31326947 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic risk factors
Number of subjects: 1049
Study 31326947 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk class membership
Number of subjects: 1049
Study 31730473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual and Marital Enrichment package
Number of subjects: 200
Study 31730473 — intervention group
Group type: COMPARATOR
Intervention: Routine care at health centers (Control)
Number of subjects: 200
Study 28854208 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate group (oral iron started concurrently with antimalarial treatment)
Number of subjects: 0
Study 28854208 — intervention group
Group type: COMPARATOR
Intervention: Delayed group (oral iron started 28 days after antimalarial treatment)
Number of subjects: 0
Study 25819861 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention conducted by a nurse focusing on medication goals, medication-symptom associations, and symptom response plan
Number of subjects: 86
Study 25819861 — intervention group
Group type: COMPARATOR
Intervention: Usual care (attention control group) with unrelated follow-up calls
Number of subjects: 86
Study 23852658 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 7 mg
Number of subjects: 1086
Study 23852658 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 1086
Study 23852658 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 1086
Study 21540372 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor Residual Spraying (IRS)
Number of subjects: 40
Study 21540372 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-Treated Nets (ITNs)
Number of subjects: 40
Study 21540372 — intervention group
Group type: COMPARATOR
Intervention: Environmental Management (EVM)
Number of subjects: 40
Study 21540372 — intervention group
Group type: COMPARATOR
Intervention: No Intervention
Number of subjects: 40
Study 19453964 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian male patient scenario with Blue Cross health insurance
Number of subjects: 90
Study 19453964 — intervention group
Group type: COMPARATOR
Intervention: African American male patient scenario with Medicaid
Number of subjects: 90
Study 16928441 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 10
Study 16928441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15301924 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (200 mg, two oral doses)
Number of subjects: 10
Study 15301924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11552858 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy during the intubated phase
Number of subjects: 236
Study 11552858 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy commenced only once extubated (Control)
Number of subjects: 236
Study 9204360 — intervention group
Group type: EXPERIMENTAL
Intervention: iopentol
Number of subjects: 80
Study 9204360 — intervention group
Group type: COMPARATOR
Intervention: iohexol
Number of subjects: 80
Study 8491638 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 612
Study 8491638 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 612
Study 8491638 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 612
Study 3325256 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with ofloxacin during granulocytopenia after cytostatic treatment
Number of subjects: 42
Study 3325256 — intervention group
Group type: COMPARATOR
Intervention: Control phases (no ofloxacin prophylaxis) during cytostatic treatment
Number of subjects: 42
Study 3325256 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with ofloxacin
Number of subjects: 42
Study 28732068 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (PQ)
Number of subjects: 0
Study 28732068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28732068 — intervention group
Group type: COMPARATOR
Intervention: PQ and Placebo
Number of subjects: 0
Study 28732068 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-species infections
Number of subjects: 0
Study 26276922 — intervention group
Group type: EXPERIMENTAL
Intervention: Body modifications (tattoos or piercings)
Number of subjects: 449
Study 26276922 — intervention group
Group type: COMPARATOR
Intervention: Control group (no body modifications)
Number of subjects: 449
Study 24626975 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological remediation program associated with reading and writing (GI)
Number of subjects: 20
Study 24626975 — intervention group
Group type: COMPARATOR
Intervention: Control group (GII)
Number of subjects: 20
Study 21355965 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound training using a simulator (15 cases)
Number of subjects: 13
Study 21355965 — intervention group
Group type: COMPARATOR
Intervention: Endobronchial ultrasound training using patients (15-25 cases)
Number of subjects: 13
Study 18652710 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 20
Study 18652710 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 20
Study 16865084 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 6% (HAES)
Number of subjects: 20
Study 16865084 — intervention group
Group type: COMPARATOR
Intervention: Albumin 20% (HA)
Number of subjects: 20
Study 14662531 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy
Number of subjects: 149
Study 14662531 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein resection
Number of subjects: 149
Study 14662531 — intervention group
Group type: COMPARATOR
Intervention: Standard resection
Number of subjects: 149
Study 14662531 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival in patients with ductal adenocarcinoma
Number of subjects: 149
Study 11053009 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg aspirin
Number of subjects: 0
Study 11053009 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg aspirin
Number of subjects: 0
Study 11053009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8764801 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact diode laser transscleral cyclophotocoagulation (TSCPC)
Number of subjects: 27
Study 1417485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic dissector
Number of subjects: 73
Study 1417485 — intervention group
Group type: COMPARATOR
Intervention: Electrosurgery
Number of subjects: 73
Study 1417485 — intervention group
Group type: COMPARATOR
Intervention: Laser
Number of subjects: 73
Study 2435449 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 80
Study 2435449 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 80
Study 2435449 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise scheme (including imipramine, amitriptyline, mianserin, phenothiazine, clonazepam)
Number of subjects: 80
Study 2435449 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine or amitriptyline (150 mg)
Number of subjects: 80
Study 31604654 — intervention group
Group type: EXPERIMENTAL
Intervention: Enlarged left atrial volume index (eLAVI)
Number of subjects: 1534
Study 29508373 — intervention group
Group type: EXPERIMENTAL
Intervention: EHBM subscale - Self-efficacy
Number of subjects: 1016
Study 29508373 — intervention group
Group type: EXPERIMENTAL
Intervention: EHBM subscale - Perceived benefits
Number of subjects: 1016
Study 29508373 — intervention group
Group type: EXPERIMENTAL
Intervention: EHBM subscale - Perceived barriers
Number of subjects: 1016
Study 29508373 — intervention group
Group type: EXPERIMENTAL
Intervention: EHBM subscale - Perceived severity
Number of subjects: 1016
Study 29508373 — intervention group
Group type: EXPERIMENTAL
Intervention: EHBM subscale - Parental knowledge
Number of subjects: 1016
Study 26767629 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vitamin D3 (cholecalciferol; 2000 IU/d) and active marine omega‐3 fatty acids (Omacor® fish oil, eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA], 1g/d)
Number of subjects: 25874
Study 26767629 — intervention group
Group type: COMPARATOR
Intervention: Active vitamin D and omega‐3 placebo
Number of subjects: 25874
Study 26767629 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D placebo and active marine omega‐3 fatty acids
Number of subjects: 25874
Study 26767629 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D placebo and omega‐3 placebo
Number of subjects: 25874
Study 24619062 — intervention group
Group type: EXPERIMENTAL
Intervention: High Pressure (n=147) - MAP maintained between 75-85 mmHg during CPB with norepinephrine
Number of subjects: 300
Study 24619062 — intervention group
Group type: COMPARATOR
Intervention: Control (n=145) - MAP maintained between 50-60 mmHg
Number of subjects: 300
Study 22258266 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-reduced diets emphasizing fat, protein, or carbohydrate
Number of subjects: 424
Study 20108108 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate and glucosamine (1,600 mg oral mixture, twice daily for 8 months)
Number of subjects: 80
Study 20108108 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 8 months)
Number of subjects: 80
Study 20108108 — intervention group
Group type: COMPARATOR
Intervention: Comparison between experimental and control groups
Number of subjects: 80
Study 17588298 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarter-dose titration and acetaminophen
Number of subjects: 47
Study 17588298 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarter-dose titration and ibuprofen
Number of subjects: 47
Study 17588298 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose titration and acetaminophen
Number of subjects: 47
Study 17588298 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose titration and ibuprofen
Number of subjects: 47
Study 17588298 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose therapy plus acetaminophen
Number of subjects: 47
Study 17588298 — intervention group
Group type: COMPARATOR
Intervention: No titration (control group)
Number of subjects: 47
Study 16305583 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin
Number of subjects: 0
Study 12160284 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% xylometazoline hydrochloride (five drops)
Number of subjects: 80
Study 12160284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10441974 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate via nebulizers at a dosage of 2 mg twice daily for 4 weeks
Number of subjects: 20
Study 10441974 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 8527276 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol ('Colestid Orange')
Number of subjects: 55